Medicine and Dentistry
Non Small Cell Lung Cancer
92%
Epidermal Growth Factor Receptor
67%
Lung Cancer
37%
Gefitinib
23%
Non-Small Cell Lung Cancer
23%
Entrectinib
22%
Progression Free Survival
22%
Lung Adenocarcinoma
21%
Epidermal Growth Factor Receptor Kinase Inhibitor
19%
Neoplasm
19%
Overall Survival
17%
Metastatic Carcinoma
17%
Disease
15%
Adenocarcinoma
12%
Osimertinib
10%
Prognostic Factor
9%
Cerebrospinal Fluid
9%
Lorlatinib
9%
Computer Assisted Tomography
9%
Crizotinib
9%
Liquid Biopsy
8%
Tyrosine-Kinase Inhibitor
8%
Adverse Event
8%
Malignant Neoplasm
8%
Durvalumab
8%
Next Generation Sequencing
8%
Radiation Therapy
8%
Arm
7%
Cancer Cell
6%
Low Drug Dose
6%
Exon
6%
Cell-Free DNA
6%
Systemic Therapy
6%
Ticilimumab
6%
Small Cell Lung Cancer
6%
Pembrolizumab
6%
Predictive Factor
6%
Circulating Tumor Cell
5%
Solid Malignant Neoplasm
5%
Multivariate Analysis
5%
Central Nervous System Metastasis
5%
Cisplatin
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
99%
Progression Free Survival
29%
Lung Cancer
28%
Gefitinib
26%
Epidermal Growth Factor Receptor Kinase Inhibitor
24%
Entrectinib
22%
Lung Adenocarcinoma
21%
Overall Survival
21%
Erlotinib
20%
Neoplasm
19%
Disease
18%
Chemotherapy
18%
Osimertinib
15%
Protein Tyrosine Kinase Inhibitor
14%
Adverse Event
12%
Ramucirumab
11%
Placebo
10%
Adenocarcinoma
9%
Malignant Neoplasm
9%
Brain Metastasis
9%
Lorlatinib
9%
Crizotinib
9%
Solid Malignant Neoplasm
9%
Disease Exacerbation
9%
Durvalumab
8%
Small Cell Lung Cancer
6%
Nivolumab
5%
Immune Checkpoint Inhibitor
5%